GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [PSA] receptor is not what most of this community thinks it is — 16 comments in the full submission. View in context.
217
c/glp1science·submitted 2 months ago by u/formulary_fighter

[PSA] receptor is not what most of this community thinks it is

Questionbranch of 6 comments

receptor is not what most of this community thinks it is — with the reasoning, because a rule without a reason gets ignored. The GIP question, which is the most interesting unsettled thing in this field. Dual agonism at GIP and GLP-1 receptors produces clinical results that are robust and well replicated. What is not…

Read the full submission and all 16 comments →

This branch

6 comments, started 2 months ago
u/gustav_vermeulen20 points·2 months ago

Started reading limitations sections first. It has changed how much weight I give to almost everything posted here.

replysharereportpermalink
u/incretin_ivyMOD11 points·2 months ago

Retitled to distinguish preclinical from clinical, which the original ran together.

replysharereportpermalink
u/formulary_fighterOPappeals-17 points·2 months ago

gastric emptying slows, it does not stop

replysharereportpermalink
u/emeka_chowdhury1 point·2 months ago

gastric emptying slows, it does not stop

formulary_fighter is right that mechanism gives direction and not magnitude. Worth pinning.

replysharereportpermalink
u/sanne_delgado1 point·2 months ago

mechanism explains a direction, not a magnitude

replysharereportpermalink
u/rafael_ostergaard10 points·2 months ago

Started reading limitations sections first.

Agreed — and it is why the central and peripheral stories are complementary rather than rival.

replysharereportpermalink

← back to the whole thread

About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/glp1science
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/trialwatch_theou/gastric_emptying_gu/sig_figs_sam
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →